The development programme will initially target rare inherited blood disorders including hemophilia A and B, thalassemia, and sickle cell disease.

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or ...

Dr Dylan Ryan will pursue the research after securing a highly competitive Wellcome Career Development Award valued at around ...

There are many reasons people get stuck, emotionally. Fortunately, there are a few unusual ways to start feeling better and ...

The commonly used term “lazy eye” may not always be as harmless as it sounds, with medical experts cautioning that similar symptoms in some cases could indicate serious neurological conditions, ...

EQUIGENE Therapeutics, a new spin-off biotech anchored by world-class hematology experts, marks a pivotal step in the UAE’s ...

Lazy eye is basically amblyopia, which develops in childhood due to a neurodevelopmental issue where the child is unable to ...

Texas is helping shape the future of psychedelic therapies. Here’s how they work and what access could look like.

Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...

Optometric care has advanced significantly with OCT and high-resolution retinal imaging, yet clinicians still encounter a ...